BRIEF-Remegen Says NMPA Approves Clinical Trial Of Bispecific Antibody-Drug Conjugate Rc288 For Injection

China NMPA approves RemeGen RC288 bispecific ADC Phase I/IIa trial for solid tumors

RemeGen - China Nmpa Approves Clinical Trial of Bispecific Antibody-Drug Conjugate (Bispecific ADC) Rc288 for Injection

Remegen Receives Clinical Trial Approval for Bispecific ADC Drug RC288

Vor Bio doses first patient in Phase 3 telitacicept Sjögren’s disease trial

RemeGen Returns to Profitability in 2025; Shares Jump 6%

Insilico Medicine Soars 15% After Announcing $2.75 Billion Partnership with Eli Lilly

REMEGEN Shares Surge Over 8% Following Strong Annual Results Showing Profit Turnaround

BRIEF-Remegen Posts FY Revenue RMB 3,241.6 Million

Remegen Co.,Ltd. Board Approves Multiple Proposals Including the 2025 General Manager Work Report

REMEGEN Reports Annual Profit of 710 Million Yuan, Turning Around from Prior Year Loss

REMEGEN Shares Climb Over 5% as Disitamab Vedotin Gains Fourth Indication Approval

RemeGen wins China NMPA approval for disitamab vedotin in HER2-low breast cancer with liver metastases

BRIEF-RemeGen Co Says NMPA Approved New Drug Application For Disitamab Vedotin

RemeGen Co Ltd - Approval of New Drug Application for Disitamab Vedotin by Nmpa

Remegen's ADC Therapy Disitamab Vedotin Secures Approval for New Breast Cancer Indication

Revised title

RemeGen to Hold Board Meeting to Approve Annual Results and Consider Dividend

REMEGEN Shares Climb Over 5% Following Regulatory Acceptance of RC288 Application

RemeGen Shares Surge Over 6% on Strong 2025 Profit Turnaround and Projected Cash Boost